PFE Beats Q2, Axes Two Obesity Drugs From $10B Metsera Buyout

Pfizer (PFE) beat Q2 2026 expectations on August 4, reporting EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus the $14.41 billion estimate. But the headline number was not the story. Pfizer discontinued four clinical-stage programs in its quarterly pipeline cleanup, including MET-224o, an oral GLP-1 receptor agonist acquired in the $10 billion Metsera buyout, and PF-07976016, a Phase 2 GIPR antagonist. PFE closed at $25.56 with a market cap of $144.8 billion.

The numbers

• Q2 revenue: $15.03 billion (beat $14.41B consensus)
• Q2 EPS: $0.77 (beat $0.68 consensus)
• 2026 guidance: Raised midpoint by $500M
• Discontinued: MET-224o (oral GLP-1), PF-07976016 (GIPR antagonist)
• Remaining oral GLP-1: PF-08642534/YP05002 (licensed from YaoPharma)
• Injectable GLP-1: Berobenatide (Phase 3 ongoing)

What happened

Pfizer spent $10 billion to acquire Metsera primarily for its oral obesity pipeline. MET-224o was one of Metsera’s lead oral candidates. Its discontinuation leaves Pfizer’s entire oral obesity strategy resting on a single licensed asset (YP05002 from YaoPharma) while competitors race ahead. Two of Metsera’s oral assets are now gone: MET-097o was dropped earlier, and MET-224o is the latest casualty.

The pipeline is narrowing to a single injectable (berobenatide) and a single oral (YP05002). CSO Chris Boshoff said berobenatide “can deliver weight loss comparable to tirzepatide and potentially better than semaglutide” on the Q2 earnings call. But investors will not see Phase 3 data until after Lilly and Novo have already captured the market.

For context on the broader obesity competitive dynamic, see our GLP-1 obesity market analysis.

The post-M&A cleanup problem

This is the story of what happens when a mega-acquisition meets quarterly pipeline rationalization. Pfizer paid a premium for Metsera’s “pipeline of obesity assets.” That pipeline is being pruned faster than it is advancing. The question: was Pfizer right to bet $10 billion, or did they overpay for a pipeline that is shrinking?

The contrast with Lilly is sharp. Lilly has three distinct obesity products (Mounjaro, Zepbound, Foundayo) with retatrutide approaching BLA filing. Novo Nordisk has semaglutide and CagriSema. Pfizer has berobenatide in Phase 3 and YP05002 in earlier development. That is two assets versus Lilly’s four and Novo’s three.

Risk to watch

The specific risk is berobenatide’s Phase 3 timeline. Pfizer is running the registration trial now, but the data will not arrive until 2027 at the earliest. By then, Lilly’s retatrutide may be approved and on the market. Pfizer’s obesity strategy depends on a single injectable drug whose data is two years behind the competition. If berobenatide’s Phase 3 results disappoint, Pfizer has no fallback in obesity.

Source: Fierce Biotech, Pfizer pipeline cleanup